Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

Not Applicable

Active, not recruiting

• Conditions: Vitiligo
• Interventions: Drug: Azathioprine; Drug: Tofacitinib

• Registration Number: NCT07044141
• Lead Sponsor: Lahore General Hospital

Brief Summary

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Detailed Description

Total 20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine 50mg twice daily. 10 will be given tofacitinib 5mg twice daily. For 6 months

Study Timeline

• Study Start: 2025-03-01
• Status Verified: 2025-05
• Study First Submitted: 2025-06-23
• Study First Submitted QC: 2025-06-23
• Last Update Submitted: 2025-06-23
• Study First Posted: 2025-06-29
• Last Update Posted: 2025-06-29
• Primary Completion: 2025-09-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• patient of vitiligo with any VASI both genders 18 to 60yrs

Exclusion Criteria

• pregnancy/lactation Hyerlipidrmia Patient on immunemodulator Histry pf tuberculosis Immunocompromised patients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	Azathioprine	Azathioprine is an immunomodulator used in treatment of vitiligo
Group B	Tofacitinib	Tofacitinib It is a Janu kinase pathway inhibitor

Primary Outcome Measures

Name	Time	Method
VASI improvement upto 50%	6 months	Study will be considered efficacious if 50% improvement in VASI from baseline is seen by end of 6 months of study

Trial Locations

Locations (1)

Lahore general.hospital; 🇵🇰 Lahore, Punjab, Pakistan